Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) FCF Margin: 2011-2025

Historic FCF Margin for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to -0.80%.

  • Adma Biologics' FCF Margin fell 2080.00% to -0.80% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.34%, marking a year-over-year decrease of 1240.00%. This contributed to the annual value of 25.90% for FY2024, which is 2434.00% up from last year.
  • As of Q3 2025, Adma Biologics' FCF Margin stood at -0.80%, which was down 105.22% from 15.34% recorded in Q2 2025.
  • Adma Biologics' FCF Margin's 5-year high stood at 40.66% during Q2 2024, with a 5-year trough of -223.07% in Q1 2021.
  • Moreover, its 3-year median value for FCF Margin was 10.21% (2023), whereas its average is 7.30%.
  • Its FCF Margin has fluctuated over the past 5 years, first soared by 18,912bps in 2021, then crashed by 2,531bps in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' FCF Margin stood at -67.53% in 2021, then spiked by 4,527bps to -22.26% in 2022, then surged by 4,445bps to 22.19% in 2023, then soared by 1,818bps to 40.37% in 2024, then crashed by 2,080bps to -0.80% in 2025.
  • Its FCF Margin stands at -0.80% for Q3 2025, versus 15.34% for Q2 2025 and -21.23% for Q1 2025.